SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Suva LJ, Gaddy D, Perrien DS, Thomas RL, Findlay DM 2005 Regulation of bone mass by mechanical loading: Microarchitecture and genetics. Curr Osteoporos Rep 3: 4651.
  • 2
    Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L 2009 Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 24: 1651 1661.
  • 3
    ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL 2008 Osteocyte-derived sclerostin inhibits bone formation: Its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90 (Suppl 1): 3135.
  • 4
    Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537543.
  • 5
    Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577589.
  • 6
    Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2002 Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39: 9197.
  • 7
    Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860869.
  • 8
    Robling AG, Bellido T, Turner CH 2006 Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6: 354.
  • 9
    Jilka RL 2009 Inhibiting the inhibitor: A new route to bone anabolism. J Bone Miner Res 24: 575577.
  • 10
    Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825837.
  • 11
    Lee K, Jessop H, Suswillo R, Zaman G, Lanyon L 2003 Endocrinology: Bone adaptation requires oestrogen receptor-alpha. Nature 424: 389.
  • 12
    Frost HM 1987 Bone “mass” and the “mechanostat”: A proposal. Anat Rec 219: 19.
  • 13
    Gu G, Hentunen TA, Nars M, Harkonen PL, Väänänen HK 2005 Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 10: 583595.
  • 14
    Huang QY, Li GH, Kung AW 2009 The −9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone 45: 289294.